Sucampo Pharmaceuticals, Inc. Release: AMITIZA® (Lubiprostone) Receives National Institute for Clinical Excellence (NICE) Recommendation
BETHESDA, Md., June 17, 2014 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced that the United Kingdom's (U.K.) National Institute of Health and Care Excellence (NICE) has released a Final Appraisal Determination with guidance for the recommendation of the use of AMITIZA® (lubiprostone) in the treatment of chronic idiopathic constipation (CIC) and associated symptoms in adults who have failed laxatives.
Help employers find you! Check out all the jobs and post your resume.